Werewolf Therapeutics (HOWL) Income from Continuing Operations (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Income from Continuing Operations of 6960000.0 for Q2 2026, up 138.68% year-over-year from 2916017.32 in Q2 2025, and up 148.99% on a QoQ basis from 14206000.0 in Q1 2026.
Werewolf Therapeutics (HOWL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 6960000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 6960000.0, up 138.68% year-over-year; the trailing twelve-month figure through Jun 2026 was 34842000.0 (up 51.63% YoY), and the FY2025 annual result was 144157000.0, down 7.04% from the prior year.
- Income from Continuing Operations climbed to 6960000.0 in Q2 2026, from 14206000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6960000.0 in Q2 2026 and troughed at 19008000.0 in Q4 2024.
- A 5-year average of 12874722.22 and a median of 14540500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2024, when Income from Continuing Operations slumped 260.91%; it then soared 138.68% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 12000000.0 in 2022, then gained by 0.02% to 11997000.0 in 2023, then tumbled by 58.44% to 19008000.0 in 2024, then surged by 46.22% to 10223000.0 in 2025, then jumped by 168.08% to 6960000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 6960000.0 in Q2 2026, 14206000.0 in Q1 2026, and 10223000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 6.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.96 Mn |
| Mar 31, 2026 | -14.21 Mn |
| Dec 31, 2025 | -11.78 Mn |
| Sep 30, 2025 | -17.37 Mn |
| Jun 30, 2025 | -19.59 Mn |
| Mar 31, 2025 | -18.26 Mn |
| Dec 31, 2024 | -20.31 Mn |
| Sep 30, 2024 | -16.77 Mn |
| Jun 30, 2024 | -18.31 Mn |
| Mar 31, 2024 | -16.19 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.28 Mn |
| Jun 30, 2023 | -5.07 Mn |
| Mar 31, 2023 | -10.88 Mn |
| Dec 31, 2022 | -12.00 Mn |
| Sep 30, 2022 | -11.95 Mn |
| Jun 30, 2022 | -14.88 Mn |
| Mar 31, 2022 | -15.33 Mn |
| Dec 31, 2021 | -17.92 Mn |
| Sep 30, 2021 | -13.74 Mn |